A Double-Blind, Randomized, Placebo Controlled, 2-Period Crossover Study to Evaluate the Effect of a Single Dose of JNJ-28431754 (Canagliflozin) on Gastrointestinal Glucose Absorption and Metabolism in Healthy Subjects.
Phase of Trial: Phase I
Latest Information Update: 14 Feb 2013
At a glance
- Drugs Canagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- 25 Sep 2012 Results will be presented at EASD-2012 according to a Janssen Research and Development media release.
- 18 Oct 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 18 Oct 2011 Actual patient number is 26 according to ClinicalTrials.gov.